

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC. and
WATSON LABORATORIES, INC.,

Petitioners,

v.

MERCK SHARP & DOHME CORP.

Patent Owner.

U.S. Patent No. 7,326,708 to Cypes et al.

Issue Date: February 5, 2008

Title: Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

Inter Partes Review No.: IPR2020-01045

Declaration of Dr. Leonard Chyall, Ph.D.

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

Declaration of Leonard Chyall, Ph.D.

Table of Contents

I.	INTRODUCTION.....	1
II.	MY EXPERIENCE AND QUALIFICATIONS	3
III.	LIST OF MATERIALS CONSIDERED	8
IV.	LEGAL STANDARD	9
	A. Anticipation.....	10
	B. Obviousness	11
V.	BACKGROUND.....	14
VI.	PERSON OF ORDINARY SKILL IN THE ART (“POSA”).....	15
VII.	THE ’708 PATENT.....	16
VIII.	CLAIM CONSTRUCTION	21
IX.	ANTICIPATION.....	22
	A. Ground 1: WO 03/004498 anticipates Claims 1-3, 17, 19, and 21-23 of the ’708 patent.....	22
	1. Disclosure of WO ’498.....	23
	2. Claim 1 of the ’708 Patent.....	33
	3. Claim 2 of the ’708 Patent.....	36
	4. Claim 3 of the ’708 Patent.....	36
	5. Claim 17 of the ’708 Patent.....	37
	a) A pharmaceutical composition comprising.....	38
	b) a therapeutically effective amount of the salt according to claim 2	38
	c) in association with one or more pharmaceutically acceptable carriers	39
	6. Claim 19 of the ’708 Patent.....	39
	a) A method for the treatment of type 2 diabetes comprising.....	39

Declaration of Leonard Chyall, Ph.D.

b)	administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 2 or a hydrate thereof.....	39
7.	Claims 21-22 of the '708 Patent	40
8.	Claim 23 of the '708 Patent	42
B.	Ground 2: Claims 1-3, 17, 19, and 22-23 Are Anticipated by the '871 Patent	43
1.	Disclosure of the '871 Patent.....	43
2.	Claims 1 and 2	43
3.	Claim 3	44
4.	Claims 17 and 19	45
5.	Claim 21.....	47
6.	Claim 22.....	48
7.	Claim 23.....	48
X.	OBVIOUSNESS	48
A.	Ground 3: Claims 3, 17, 19, and 21-23 Would Have Been Obvious in View of WO '498	49
1.	The Level of Ordinary Skill in the Pertinent Art.....	49
2.	The Scope and Content of the Prior Art	49
a)	WO '498 (EX1004).....	49
b)	Claim 3	49
c)	Claim 17	51
a)	“A pharmaceutical composition	
b)	comprising”	51
c)	“A therapeutically effective amount of the salt according to claim 2”	51
c)	“In association with one or more pharmaceutically acceptable carriers”	51
d)	Claim 19	52

Declaration of Leonard Chyall, Ph.D.

a)	“A method for the treatment of type 2 diabetes comprising”	52
b)	“administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 2 or a hydrate thereof”	52
e)	Claim 21	52
f)	Claim 22	54
g)	Claim 23	54
B.	Ground 4: Claims 1-3, 17, 19, and 21-23 Would Have Been Obvious in View of WO ’498 and Bastin	54
1.	The Level of Ordinary Skill in the Pertinent Art	54
2.	The Scope and Content of the Prior Art	54
a)	WO ’498 (EX1004)	54
b)	Bastin (EX1006)	54
3.	The Differences Between the Claims and Prior Art	56
a)	Claim 1	56
a)	WO ’498 and Bastin Would Have Rendered the Phosphoric Acid Salt Obvious*	56
b)	Claims 2 and 3	60
c)	Claims 17 and 19	61
d)	Claims 21-23	62

* [This section is so numbered in *Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-00040, Ex. 1002, Declaration of Dr. Mukund Chorghade, Ph.D. (Oct. 29, 2019).]

Declaration of Leonard Chyall, Ph.D.

C.	Ground 5: Claim 4 Would Have Been Obvious in View of WO '498, Bastin, and Brittain	63
1.	The Level of Ordinary Skill in the Pertinent Art.....	63
2.	The Scope and Content of the Prior Art	64
a)	WO '498 (EX1004) and Bastin (EX1006).....	64
b)	Brittain (EX1005).....	64
3.	The Differences Between the Claim and Prior Art.....	65
a)	Claim 4	65
D.	Ground 6: Claim 4 Would Have Been Obvious in View of WO'498 and Brittain.....	66
1.	The Level of Ordinary Skill in the Pertinent Art.....	66
2.	The Scope and Content of the Prior Art	66
a)	WO '498 (EX1004) and Brittain (EX1005).....	66
3.	The Differences Between the Claim and Prior Art.....	66
XI.	SECONDARY CONSIDERATIONS.....	68

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.